Menu
Search
|

Menu

Close
X

Ra Pharmaceuticals Inc RARX.OQ (NASDAQ Stock Exchange Global Market)

25.77 USD
+0.00 (+0.00%)
As of Sep 18
Previous Close 25.77
Open 25.71
Volume 107,305
3m Avg Volume 185,220
Today’s High 25.91
Today’s Low 24.57
52 Week High 36.92
52 Week Low 11.35
Shares Outstanding (mil) 22.61
Market Capitalization (mil) 326.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
2
FY17
0
FY16
2
EPS (USD)
FY19
-0.969
FY18
-2.077
FY17
-2.409
FY16
-1.020
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
3.39
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
0.00
14.55
LT Debt to Equity (MRQ)
vs sector
0.00
10.20
Return on Investment (TTM)
vs sector
-60.75
14.48
Return on Equity (TTM)
vs sector
-174.09
15.78

EXECUTIVE LEADERSHIP

Edward Mathers
Independent Chairman of the Board, Since 2010
Salary: --
Bonus: --
Douglas Treco
President, Chief Executive Officer, Co-Founder, Director, Since 2008
Salary: $500,000.00
Bonus: --
David Lubner
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $377,000.00
Bonus: --
Simon Read
Chief Scientific Officer, Since 2016
Salary: --
Bonus: --
Ramin Farzaneh-Far
Chief Medical Officer, Since 2016
Salary: $400,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

87 Cambridgepark Dr
CAMBRIDGE   MA   02140-2311

Phone: +1617.4014060

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system. It is developing its lead product candidate, RA101495, a self-administered subcutaneous (SC) injection. RA101495 is injected into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The Company is also developing RA101495 to treat other debilitating complement-mediated diseases such as generalized myasthenia gravis (gMG) and lupus nephritis (LN). It also focuses on discovery and preclinical programs targeting selective inhibition of other uncontrolled complement pathway factors to treat a variety of ophthalmic, renal and inflammatory diseases. The Company uses its Extreme Diversity platform, macrocyclic peptide chemistry technology which produces synthetic macrocyclic peptides.

SPONSORED STORIES